Table 2.

Summary table of drugs used in the task. DA, dopaminergic; DAT, dopamine active transporter; NMDAR, N-methyl-D-aspartate receptor; VMAT-2, vesicular monoamine transporter 2

Drug	Doses used (mg/kg)	Pretreatment time (mins)	Primary mechanism of action at doses selected
Haloperidol	0.01, 0.03, and 0.1	60	Antagonism of D2 receptors resulting in reduced DA transmission.
Amphetamine	0.1, 0.3, and 1.0	15	Stimulation of DA release and inhibition of DA uptake via VMAT-2 interaction resulting in increased DA transmission.
CP101-606	1.0, 3.0, and 10.0	30	Modulation of glutamate signaling at GluN2B containing NMDARs.
Methylphenidate	1.0, 3.0, and 10.0	15	Inhibition of DAT, reducing DA uptake and resulting in increased DA transmission.
Tetrabenazine	0.1, 0.3, and 1.0	90	Inhibition of monoamine uptake into vesicles of presynaptic neurons by binding VMAT-2, resulting in decreased DA transmission.